Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus
CA 2450939 C · Owner: Inhibitex, Inc. · Inventors: Roche, Fiona; Foster, Timothy J.; Pallen, Mark
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Polyclonal and monoclonal antibodies which are cross-reactive to both coagulase-positive staphylococcus bacteria such as S. hemolyticus, are , provided which can recognize surface proteins from both coagulase-positive and coagulase negative staph bacteria. The antibodies may be generated from surface proteins that have been isolated on the basis of characteristics that may be common between S. aureus and coagulase-negative staphylococci and , these recombinant surface proteins are used to generate the antibodies of the invention. There is also provided vaccines and methods which utilize these proteins and antibodies for the treatment or protection against a wide variety of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 17, 2002 and granted November 6, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended June 17, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 17, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.